RXRX NASDAQ
Recursion Pharmaceuticals, Inc.
1W: +10.2%
1M: +21.9%
3M: +4.0%
YTD: -1.9%
1Y: -19.2%
3Y: -47.0%
5Y: -83.2%
$4.12
+0.05 (+1.23%)
Weekly Expected Move ±12.2%
$3
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
21 relationships19
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2021-12-07
Earliest Filing
2026-03-02
Latest Filing
partner: 9
investor: 7
target: 3
Counterparties (Filed by RXRX)
19 relationshipsCompanies named in RXRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Exscientia plc | EXAI | target | Target company acquired by Recursion Pharmaceuticals, Inc. via a scheme of arrangement. | 2024-11-20 | View |
| Exscientia plc | — | target | Target company to be acquired by Recursion Pharmaceuticals, Inc. via a scheme of arrangement. | 2024-11-06 | View |
| Exscientia plc | — | target | Target company to be acquired by Recursion Pharmaceuticals, Inc. via a scheme of arrangement. | 2024-08-08 | View |
| Tempus Labs, Inc. | — | partner | Entered into a Master Agreement for data licensing and AI model development services. | 2023-11-09 | View |
| Bayer AG | BYMOF | partner | Amended and restated a Research Collaboration and Option Agreement to focus on oncology projects. | 2023-11-09 | View |
| NVIDIA | NVDA | partner | Mentioned as a collaborator in a press release regarding updates to existing collaborations. | 2023-11-09 | View |
| NVIDIA Corporation | NVDA | investor | Private placement of Class A common stock for approximately $50 million. | 2023-07-12 | View |
| Kinnevik AB | — | investor | Qualified institutional buyer and institutional accredited investor participating in the private placement. | 2022-10-25 | View |
| Baillie Gifford | — | investor | Qualified institutional buyer and institutional accredited investor participating in the private placement. | 2022-10-25 | View |
| Mubadala Investment Company | — | investor | Qualified institutional buyer and institutional accredited investor participating in the private placement. | 2022-10-25 | View |
| Laurion Capital Management | — | investor | Qualified institutional buyer and institutional accredited investor participating in the private placement. | 2022-10-25 | View |
| Invus | — | investor | Qualified institutional buyer and institutional accredited investor participating in the private placement. | 2022-10-25 | View |
| Platinum Investment Management Limited | — | investor | Responsible entity of Platinum International Health Care Fund, participating as a qualified institutional buyer and inst | 2022-10-25 | View |
| Morgan Stanley & Co. LLC | MS-PL | partner | Lead placement agent for the private placement. | 2022-10-25 | View |
| Berenberg Capital Markets LLC | — | partner | Co-placement agent for the private placement. | 2022-10-25 | View |
| KeyBanc Capital Markets Inc. | — | partner | Co-placement agent for the private placement. | 2022-10-25 | View |
| Needham & Company, LLC | — | partner | Co-placement agent for the private placement. | 2022-10-25 | View |
| Genentech, Inc. | — | partner | Entered into a Collaboration and License Agreement with Recursion Pharmaceuticals for gastrointestinal cancer and neuros | 2021-12-07 | View |
| F. Hoffmann-La Roche Ltd | — | partner | Jointly with Genentech, entered into a Collaboration and License Agreement with Recursion Pharmaceuticals for gastrointe | 2021-12-07 | View |
Mentioned As Counterparty
2 mentionsOther companies that named RXRX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| RLYB Rallybio Corp | partner | Counterparty in a Membership Interest Purchase Agreement referenced in the CVR Agreement. | 2026-03-02 | View |
| RLYB Rallybio Corp | target | Acquired 50% of ENPP1 JV membership interests from Rallybio in exchange for cash and Class A Common Stock | 2025-07-08 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Material Agreement | Agreement | View |
| 2026-08-05 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-30 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-25 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-26 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-10-29 | Other Events | View | |
| 2025-08-29 | Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-08 | Unregistered Sales of Equity Securities; Regulation FD Disclosure; Other Events; Financial Statement | View | |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-10 | Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-05-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-18 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR